March 20, 2025 — It’s unmistakable. A quick look at the upcoming meeting of the American College of Cardiology in Chicago tells us that obesity care has a growing role in cardiology. The meeting starts March 29 and a total of 27 educational sessions will focus on obesity. Three late breaking publications – two for semaglutide and one for […]
March 18, 2025 — We’ve been living with the consensus report of the Lancet Commission on Clinical Obesity now for two months. Enough time has passed for feelings about the strengths and limitations of this work to take shape. A new commentary in the BMJ yesterday brings a sharp focus to the struggle of defining and dealing with current […]
March 17, 2025 — Nothing succeeds like success. And thus, the success of GLP-1 medicines for obesity seems to be prompting a re-ordering of marketing for packaged food. Under the Healthy Choice brand, ConAgra has begun promoting an ON TRACK badge that identifies their meals as “GLP-1 Friendly,” as well as high in fiber and protein. ConAgra Senior VP […]
March 11, 2025 — Drug development is tricky. If you want evidence for just how tricky it is, a quick look at the experience with CagriSema will give you a pretty good idea. Yesterday, Novo Nordisk announced topline results of this drug from their REDEFINE 2 clinical trial. Their press release talked about “superior results” for people with overweight […]
March 6, 2025 — Prices are moving quickly for people seeking obesity treatment with semaglutide and tirzepatide. Last week, Lilly offered another price cut for Zepbound. At the time, we noted inaction from Novo Nordisk on this front. But it barely took a week for this formerly unchallenged market leader to step up and respond with a huge price […]
March 5, 2025 — FDA seems to be moving toward giving more and more attention to accurate drug labeling for people with obesity. Yesterday, Medscape published a deep exploration of this issue. The timing coincided nicely with Obesity Care Week and World Obesity Day, Responding to Medscape Medical News, FDA made reference to a workshop they sponsored on the […]
March 4, 2025 — It is about time. The world is waking up to the realization that rising global obesity is not a problem of personal failures. Rather, it is the product of systems with the unintended effect of promoting obesity while denying people care for this chronic disease. At the heart of World Obesity Day 2025 is the […]
March 1, 2025 — CDC recently told us that diagnoses of diabetes have been rising – very much in line with the decades-long rise in obesity prevalence. As if that news were not sufficiently troubling, a research letter in JAMA this week tells us that adequate control of diabetes is going down. Most of that decline is happening in […]
February 27, 2025 — More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]
February 25, 2025 — A concern is surfacing as obesity treatments become more and more effective. The measurement for success has long been percent weight loss. But thoughtful people have always known that the right target for obesity care was actually improved health. It was okay to focus on weight as a measure of effectiveness when the the effect […]
